Facebook vs a2z Radiology AI

Side-by-side comparison of AI visibility scores, market position, and capabilities

Facebook

LeaderEntertainment

Social Media

Meta (NASDAQ: META) flagship social network with 2.1B+ daily users and $164.5B group revenue; Reels, Groups, and Marketplace competing with TikTok and YouTube for global social media advertising share.

AI VisibilityBeta
Overall Score
A84
Category Rank
#2 of 3
AI Consensus
53%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
78
Gemini
76

About

Facebook is Meta Platforms' (NASDAQ: META) flagship social networking application — the world's largest social network with 3.3+ billion daily active people across Meta's family of apps (Facebook, Instagram, Messenger, WhatsApp) — providing social feed, community groups, events, Marketplace, Reels short video, and Facebook Watch for the global social media ecosystem. Meta generated $164.5 billion in total revenue in fiscal year 2024 with Facebook as the core advertising-supported platform, serving 2.1+ billion daily active users on Facebook specifically, the majority in Southeast Asia, India, Latin America, and Africa where Facebook remains the primary social internet experience.

Full profile

a2z Radiology AI

EmergingEnterprise AI

Medical Imaging AI

a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.

About

a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.